Email updates

Keep up to date with the latest news and content from Diagnostic Pathology and BioMed Central.

Open Access Research

Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma

Xiaodong Guo12, Lu Xiong3, Ting Sun4, Ruiyun Peng3, Lin Zou5, Haiyan Zhu5, Jing Zhang3, Hanwei Li1* and Jingmin Zhao1*

Author affiliations

1 Postgraduate Medical School of PLA, Beijing, 100853, China

2 302 Hospital of PLA, Beijing, 100039, China

3 Beijing Institute of Radiation Medicine, 27 Taiping Road, Beijing, 100850, China

4 Navy General Hospital of PLA, Beijing, 100049, China

5 PLA GENERAL HOSPITAL, Beijing, 100853, China

For all author emails, please log on.

Citation and License

Diagnostic Pathology 2012, 7:44  doi:10.1186/1746-1596-7-44

Published: 19 April 2012

Abstract

Background

SOX9 as a member of the SOX (SRY [sex determining region Y] box) gene superfamily has been previously demonstrated to be a proto-oncogene in a variety of malignancies. However, the clinical significance of SOX9 expression in hepatocellular carcinoma (HCC) remains unclear. The aim of this study was to investigate the expression of SOX9 in HCC and determine its correlation with tumor progression and prognosis.

Methods

One-hundred and thirty HCC patients who had undergone curative liver resection were selected and immunohistochemistry, Western blotting, and quantitative real time polymerase chain reaction (Q-PCR) were performed to analyze SOX9 expression in the respective tumors.

Results

Immunohistochemistry, Western blotting, and Q-PCR consistently confirmed SOX9 overexpression in HCC tissues compared with their adjacent nonneoplastic tissues (P ≪ 0.01). Additionally, immunostaining showed more SOX9 positive cells in the higher tumor stage (T3 ~ 4) and tumor grade (G3) than in the lower tumor stage (T1 ~ 2, P = 0.03) and tumor grade (G1 ~ 2, P = 0.01), respectively. Moreover, HCC patients with high SOX9 expression were significantly associated with lower 5-year overall survival (P ≪ 0.01) and lower 5-year disease-free survival (P ≪ 0.01), respectively. The Cox proportional hazards model further showed that SOX9 over-expression was an independent poor prognostic factor for both 5-year disease-free survival (hazards ratio [HR] = 2.621, 95% confidence interval[CI] = 1.548-5.829, P = 0.01) and 5-year overall survival (HR = 3.825, CI = 1.638-7.612, P = 0.003) in HCC.

Conclusion

Our data suggest for the first time that the overexpression of SOX9 protein in HCC tissues is of predictive value on tumor progression and poor prognosis.

Virtual slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/9029740396926377 webcite.

Keywords:
Hepatocellular carcinoma; SOX9; Expression; Tumor progression; Prognosis